Bortezomib in combination with epirubicin, dexamethasone and thalidomide is a highly effective regimen in the treatment of multiple myeloma: a single-center experience

Shuqing Lü, Jianmin Wang , Jianmin Yang et al. Int J Hematol (2009) 89:34–38Department of Hematology, Changhai Hospital,Second Military Medi


Shuqing Lü, Jianmin Wang , Jianmin Yang et al. Int J Hematol (2009) 89:34–38

Department of Hematology, Changhai Hospital,
Second Military Medical University,
174 Changhai Road, 200433 Shanghai, China

Abstract The aim of the present study was to evaluate
the effectiveness of bortezomib combined with epirubicin,
dexamethasone, and thalidomide (BADT) for the treatment
of multiple myeloma (MM). The BADT regimen consisted
of a maximum of eight 4-week cycles of: intravenous
bortezomib (1.0 mg/m2) and intravenous epirubicin
(12 mg/m2) on days 1, 4, 8, and 11; dexamethasone
(20 mg) on days 1, 2, 4, 5, 8, 9, 11, and 12; and oral
thalidomide (100 mg/m2) on days 1–28. Twelve patients
with MM were included in the study, of whom four had not
been previously treated and eight had been previously
treated with at least one cycle of a systemic combined
regimen. All the patients completed at least two cycles of
treatment, with an average of five cycles; the complete
response (CR) rate was 83.3% (10/12) and stabilization of
disease was 16.7% (2/12). The average number of cycles
required to achieve CR was 1.9 (range 1–6). In three
patients, mobilization of peripheral blood stem cells
allowed a sufficient quantity of CD34? cells to be harvested
for future autotransplantation. The main adverse
reactions included peripheral neuropathy (4/12), thrombocytopenia
(3/12), electrocardiographic abnormalities
(4/12), neutropenia (5/12), and liver function impairment
(4/12), primarily grade I–II. Infection occurred in four
patients with neutropenia, including one patient who
developed sepsis. The estimated 1-year overall survival
rate was 91.7 ± 8.0%, and the estimated 1-year diseasefree
survival was 75.0 ± 12.5%. BADT is a highly effective combined regimen, with acceptable toxicity, for
the treatment of multiple myeloma.




多发性骨髓瘤,感染,糖尿病,便秘,感染,抑郁症,贫血,抽搐,脊柱侧弯,性病,。 诊疗文章网 

诊疗文章网 @ 2018